Bry Reinhardt

Bry Reinhardt has a diverse work experience, beginning with a volunteer position at Children's Specialized Hospital in 2015. Bry then served as a Youth Board Member for both MORE After School Inc. and Imagine, A Center for Coping with Loss in 2014 and 2013, respectively. In 2017, Bry began working as a Research Assistant for the UCLA Neuroscience Research Institute, the B. John Garrick Institute for the Risk Sciences, and Innovative Behavioral Therapies. Bry was also published as first author on a publication outlining the long-term effects of gene therapy for ADA-SCID in the scientific journal, Blood. In 2020, Bry was appointed as the VP of Customer Success at Popl. In 2022, they took on a Research Intern role at Cedars-Sinai, where they helped develop an investigator initiated, open-label, Phase I Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy trial and investigated new approaches to CAR T therapy and treatments for multiple myeloma.

Bry Reinhardt attended the University of California, Los Angeles from 2016 to 2020, where they earned a Bachelor of Science in Psychobiology. In 2017, they studied Physics at University College Dublin. Bry is currently attending Louisiana State University School of Medicine in New Orleans, where they are pursuing a Doctor of Medicine and a Masters in Public Health.